280 related articles for article (PubMed ID: 7532466)
1. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack?
Hofman P; Hsi BL; Manie S; Fenichel P; Thyss A; Rossi B
Breast Cancer Res Treat; 1994; 32(2):213-9. PubMed ID: 7532466
[TBL] [Abstract][Full Text] [Related]
2. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.
Thorsteinsson L; O'Dowd GM; Harrington PM; Johnson PM
APMIS; 1998 Sep; 106(9):869-78. PubMed ID: 9808413
[TBL] [Abstract][Full Text] [Related]
3. Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast.
Concha A; Ruiz-Cabello F; Cabrera T; Nogales F; Collado A; Garrido F
Eur J Immunogenet; 1995 Aug; 22(4):299-310. PubMed ID: 7495782
[TBL] [Abstract][Full Text] [Related]
4. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical reactivity of a mouse monoclonal antibody CDI 315B raised against human breast carcinoma.
Beketić-Oresković L; Sarcević B; Malenica B; Novak D
Neoplasma; 1993; 40(2):69-74. PubMed ID: 8394515
[TBL] [Abstract][Full Text] [Related]
6. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.
Kufe D; Inghirami G; Abe M; Hayes D; Justi-Wheeler H; Schlom J
Hybridoma; 1984; 3(3):223-32. PubMed ID: 6094338
[TBL] [Abstract][Full Text] [Related]
7. CD24 is a marker for human breast carcinoma.
Fogel M; Friederichs J; Zeller Y; Husar M; Smirnov A; Roitman L; Altevogt P; Sthoeger ZM
Cancer Lett; 1999 Aug; 143(1):87-94. PubMed ID: 10465342
[TBL] [Abstract][Full Text] [Related]
8. Complement-regulatory proteins in ovarian malignancies.
Bjørge L; Hakulinen J; Wahlström T; Matre R; Meri S
Int J Cancer; 1997 Jan; 70(1):14-25. PubMed ID: 8985085
[TBL] [Abstract][Full Text] [Related]
9. The expression of the complement regulators CD46, CD55, and CD59 by human sperm does not protect them from antisperm antibody- and complement-mediated immune injury.
D'Cruz OJ; Haas GG
Fertil Steril; 1993 Apr; 59(4):876-84. PubMed ID: 7681414
[TBL] [Abstract][Full Text] [Related]
10. A monoclonal antibody against human decay-accelerating factor (DAF, CD55), D17, which lacks reactivity with semen-DAF.
Hara T; Matsumoto M; Fukumori Y; Miyagawa S; Hatanaka M; Kinoshita T; Seya T; Akedo H
Immunol Lett; 1993 Aug; 37(2-3):145-52. PubMed ID: 7505002
[TBL] [Abstract][Full Text] [Related]
11. Expression of complement regulatory proteins on human eggs and preimplantation embryos.
Fenichel P; Donzeau M; Cervoni F; Menezo Y; Hsi BL
Am J Reprod Immunol; 1995 Feb; 33(2):155-64. PubMed ID: 7544131
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: implications for lymphomagenesis in acquired immunodeficiency syndrome.
Roncella S; Cutrona G; Favre A; Ulivi M; Fais F; Signorini A; Grossi CE; Chiorazzi N; Ferrarini M
Blood; 1996 Jul; 88(2):599-608. PubMed ID: 8695808
[TBL] [Abstract][Full Text] [Related]
13. Characterization of three monoclonal antibodies to membrane co-factor protein (MCP) of the complement system and quantification of MCP by radioassay.
Cho SW; Oglesby TJ; Hsi BL; Adams EM; Atkinson JP
Clin Exp Immunol; 1991 Feb; 83(2):257-61. PubMed ID: 1993359
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.
Bjørge L; Jensen TS; Matre R
Cancer Immunol Immunother; 1996 Mar; 42(3):185-92. PubMed ID: 8640847
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
[TBL] [Abstract][Full Text] [Related]
16. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
17. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
[TBL] [Abstract][Full Text] [Related]
18. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
Gelderman KA; Blok VT; Fleuren GJ; Gorter A
Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation.
Seya T; Hara T; Matsumoto M; Akedo H
J Immunol; 1990 Jul; 145(1):238-45. PubMed ID: 1694203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
